(CercleFinance.com) – Pharnext announced on Wednesday that it had consolidated its shares at the rate of one new share against 5,000 old shares, an operation intended to reduce the volatility of its share price and promote its stabilization.
The biopharmaceutical company, which is currently developing a treatment for Charcot-Marie-Tooth disease type 1A (CMT1A), explains that it ended the exchange operations yesterday, the date of the last quotation of the old shares.
The first quotation of the new shares therefore takes place today: around 10:50 am, the title lost 22% to 0.39 euro.